Details for Patent: 11,951,190
Which drugs does patent 11,951,190 protect, and when does it expire?
Patent 11,951,190 protects PLUVICTO and is included in one NDA.
This patent has eighty-three patent family members in thirty-seven countries.
Summary for Patent: 11,951,190
| Title: | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer |
| Abstract: | The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib). |
| Inventor(s): | Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike BAUDER-WÜST, Michael Eisenhut, Walter Mier, Martina BENESOVA |
| Assignee: | Novartis AG |
| Application Number: | US17/143,280 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 11,951,190
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | 11,951,190 | ⤷ Start Trial | FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY | ⤷ Start Trial | ||||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | 11,951,190 | ⤷ Start Trial | IN COMBINATION WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC ANDROGEN PATHWAY MODULATION-NAÏVE OR -SENSITIVE (MAPMN/S) PROSTATE CANCER | ⤷ Start Trial | ||||
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | 11,951,190 | ⤷ Start Trial | FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC ANDROGEN PATHWAY MODULATION-RESISTANT (MAPMR) PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,951,190
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 4095130 | ⤷ Start Trial | CA 2024 00027 | Denmark | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | LUC00352 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | 301281 | Netherlands | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | PA2024522 | Lithuania | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | 2024C/528 | Belgium | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | 122024000038 | Germany | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | CR 2024 00027 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
